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Backgrounds: To investigate the feasibility and efﬁcacy of concurrent 
hypofractionated chemo-radiotherapy using concomitant boost to gross 
tumor volume for patients with stage III non-small cell lung cancer 
(NSCLC). The hypothesis is that the shortened treatment time by hypo-
fractionated radiotherapy regimen would prevent accelerated repopula-
tion, and enhance the biological effects on cancer cells.
Methods: Forty-nine eligible patients with pathologically conﬁrmed 
Stage III NSCLC were enrolled between December of 2003 and August 
of 2005. Eighteen patients had stage IIIA and 31 patients had stage 
IIIB disease. Daily fractions of 2.4 Gy and 1.8 Gy were delivered to 
GTV and CTV to a total dose of 60 Gy and 45 Gy in 25 fractions over 
5 weeks, respectively, by using 3D-conformal radiotherapy techniques. 
All patients received concurrent weekly chemotherapy consisted of 
Paclitaxel (50 mg/m2 iv over 1 hour, days 1, 8, 15, 22, 29, 36) and Car-
boplatin (AUC=2, iv over 30 minutes, days 1, 8, 15, 22, 29, 36).
Results: With median follow-up periods of 21 (range, 16-38) months, 
median survival was 29 (range, 0.2-32) months. One and two year 
overall (OS), progression free (PFS), local progression free (LPFS), 
and distant metastases free survival (DMFS) rates were 82% and 65%, 
61% and 41%, 73% and 56%, and 85% and 72%, respectively. The 
compliance of radiotherapy was 90% (44/49 patients), and 88% (43/49) 
patients completed planned 5 cycles of chemotherapy. The response 
rate was 100% with 44% of near complete response and 56% of partial 
response. Two patients with T4 lesion (one with involvement of left 
atrium and the other with left pulmonary artery involvement) died of 
bleeding and hemoptysis during treatment (Grade 5). Acute esophagitis 
was the most common acute toxicity with twenty nine patients (59%) 
developing ≥ Grade 2 esophagitis. Five (10%) developed grade 3 he-
matologic tocicities, mostly neutropenia. Six (12%) patients developed 
late esophageal toxicity ≥ grade 3 and four (8%) had late pulmonary 
toxicities ≥ grade 3.
Conclusions: Our preliminary results are encouraging with higher 
OS and LPFS when compared to historical control. A careful patient 
selection is warranted since two patients with T4 with major vascular 
involvement died of tumor bleeding presumably due to rapid tumor 
regression at the site of major vessel involvement by accelerated radio-
therapy regimen using concomitant GTV boost. Other acute and late 
toxicities appear to be acceptable. A longer follow-up is needed.
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target and normal tissue dosimetry parameters of lung cancer 
radiotherapy? A multiple 4DCT analysis
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Background: In radiation therapy for locally advanced lung cancers, 
changes of tumor anatomy, mobility of tumor by respiration, and other 
uncertainties during the course of therapy may introduce signiﬁcant 
deviation of dose distributions from those planned initially before the 
start of therapy. Respiratory-correlated 4DCT imaging taken in a serial 
fashion during the therapy course could provide important spatio-tem-
poral information of tumors and anatomical structures. The purpose of 
this study is to understand such anatomical changes and their impact on 
the dose distributions for radiotherapy.
Methods: 4DCT imaging was repeated during every week of radia-
tion therapy using either 3D conformal or IMRT technique for a small 
cohort of non-small-cell lung cancer patients. Data from the weekly 
4DCT datasets were analyzed with respect to anatomical changes and 
tumor motion. Original treatment plans were reproduced onto weekly 
datasets using updated target and other anatomical structures, as well 
as isocenter geometry for a particular week. Dose distributions of all 
weekly plans were recalculated. Dosimetric changes to the PTV, ITV, 
and relevant normal structures relative to original treatment plans were 
analyzed. 
Results: For 5 patients who completed the study, weekly 4DCT images 
were acquired for 6 successive weeks during the course of therapy. The 
overall average (range) change in the percentage of volume of PTV 
and ITV covered by the 95% isodose (V95) between initial and during 
treatment was -4.0% (-15.3% to 2.1%) and -0.9% (-2.8% to 0.0%), 
respectively. The overall average change (range) in the dose to 95% 
of the PTV and ITV (D95) between initial and during treatment was 
-4.5Gy (-16.4Gy to 4.0Gy) and -0.5Gy (-2.4Gy to 1.2Gy), respectively. 
Initial normal tissues volumes were comparable to the weekly datasets. 
The overall mean variation (range) between initial vs. mean weekly 
percent total lung volume exceeding 20Gy (V20), mean total lung 
doses, and cord maximum doses were -0.6% (-3.5% to 2.4%), -0.4Gy 
(-2.6Gy to 1.7Gy) and 6.5Gy (-1.4Gy to 15.6Gy), respectively.
Dosimetric comparison of radiation doses to target and significant normal 
tissue volumes at planning and during the course treatment as derived from 
serial 4DCT imaging.
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Conclusions: Serial respiration-correlated CT scans revealed important 
information on dosimetric consequences of anatomical changes during 
treatment. Preliminary data showed that variations in target and normal 
tissue volumes were small in average. Nevertheless, greater changes 
were observed in certain patients with larger tumor motion and in lower 
lobe lesions; therefore, effort to include image-guidance for setup and 
frequent imaging during the course of treatment, should be studied 
further.
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Purpose: It is challenging to integrate the emerging radiation technolo-
gy and evidences into daily practice. Physicians may differ in their treat-
ment decisions due to various considerations. The purpose of this study 
is to determine whether there is a signiﬁcant difference in practicing 
radiation therapy (RT) for non-small cell lung cancer (NSCLC) between 
radiation oncologists from the United States (US) and other countries. 
Methods: Study questionnaires were designed by a panel of 8 Ameri-
can Board certiﬁed radiation oncologists. The survey was sent through 
email to radiation oncologist members of American Society of Thera-
peutic Radiology and Oncology (ASTRO) on September 10th, 2006, 
with the results collected online on March 14th, 2007. There were a 
total of 796 responses; 705 of them were considered to be valid for this 
analysis. Chi-square tests were used to test for associations between 
country and practice patterns.
Results: The respondents saw an average of 8 new cases monthly 
(range 0-25). There were 425 responses from the US and 280 from 
other countries. There was no signiﬁcant difference in choices of radia-
tion regimen for stage I peripherally located disease: 34% vs 26%, 10% 
vs 15%, and 19% vs 24%, for conventional fractionated, hypofrac-
tioned, stereotactic RT and stereotactic radiation therapy, for US and 
non-US physicians, respectively. For stage I centrally located disease, 
the majority of respondents selected fractionated radiation therapy; 
there was no signiﬁcant difference between these two groups regarding 
the choices of fractionated (79% vs 73%) vs stereotactic RT (11% vs 
12%). The choices of fractionation scheme for stereotactic RT included 
18-20Gyx3, 15-17Gyx3, 8-11Gyx5, and 10Gyx6; more physicians 
were found to select 18-20Gyx3 from the US (14.3%) than from other 
countries (5.3%, p<0.001). For stage II and III, the dominant pattern of 
practice was concurrent chemoradiation; there were more respondents 
from the US (85%) that chose concurrent chemoradiation than from 
other countries (60% and 63% for stage II and III, p<0.001). Regarding 
choices of dose fractionation, the majority of respondents (91% vs 86% 
for US and non-US respectively) selected 60-70 Gy in 1.8-2 Gy daily 
fractions when radiation was combined with chemotherapy. More US 
respondents selected >70 Gy radiation (10% vs 3.6%, p=0.085). For 
stage IV disease, dose prescriptions ranged from from 0 Gy, 2.5Gyx20, 
3Gyx15, 3Gyx10, to 2Gyx30 in 25% vs 27%, 18% vs 5%, 7% vs 8%, 
13% vs 13%, and 27% vs 21% for US and non-US respondents, respec-
tively. There were signiﬁcantly more US respondents (P<0.001) that 
selected 50 Gy in 20 fractions. 
Conclusions: Although the dominant practice patterns are similar in 
many settings, more US physicians selected larger fraction size for ste-
reotactic RT, higher total dose for fractionated RT, and more concurrent 
chemoradiation for stage II/III NSCLC. The potential reasons for and 
societal impacts of these differences should be addressed.
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Background: It has been reported that plasma TGF-β1 at the end of 
radiation therapy (RT) in lung cancer was predictive of RILT. However, 
end of treatment evaluations cannot be used to adjust initial RT. The 
purpose of this international study was to investigate whether circulat-
ing TGF-β1during RT correlates with RILT so that remaining RT could 
be adapted according to the risk of toxicity.
Methods: Patients were from two institutions: University of Michigan 
Hospital (UM) and Cancer Hospital of Peking Union Medical Col-
lege and Chinese Academy of Medical Science (PUMC). Patients with 
stage I-III non-small cell lung cancer treated with fractionated RT were 
eligible for this study. Platelet poor plasma was obtained pre-RT and 
at 4 weeks (40-50 Gy) during-RT. TGF-β1 was measured using an 
enzyme-linked immunosorbent assay. The primary endpoint for RILT 
was ≥ grade 2 radiation pneumonitis or ﬁbrosis. Radiation-induced 
pulmonary function reduction was assessed by measuring forced vital 
capacity (FVC), forced expiratory volume in the ﬁrst second (FEV1), 
and diffusing capacity for carbon monoxide (DLCO) before RT and at 
three months after RT. Logistic regression and Chi-square were used 
for statistical analysis.
Results: Sixty-four patients with a minimum follow-up of 12 months 
were included. Twenty six were from UM and 38 were from PUMC. 
Fifty-seven were male and seven were female. The median age was 60 
years. Fifty received chemotherapy concurrently (54.7%) or sequen-
tially (23.4%) with RT. The median radiation dose was 63.9 Gy and the 
median mean lung dose (MLD) was 15.7 Gy. Three months after RT, 
DLCO declined to 54.8 ± 17.3% from a pre-RT level of 64.03 ± 17.9%, 
without a signiﬁcant reduction in FVC and FEV1. Eighteen patients 
(28.1%) experienced ≥ grade 2 RILT. No signiﬁcant difference in MLD 
was found between patients with RILT and those without RILT. When 
age, gender, disease stage, administration of chemotherapy, radia-
tion dose, MLD, pre-RT FVC, pre-RT FEV1, pre-RT DLCO, pre-RT 
TGF-β1, during-RT TGF-β, and TGF-β1 ratio (during-RT/pre-RT) 
were input into a logistic regression model, TGF-β1 ratio was the only 
